Ligand structure-dependent differences in activation of estrogen receptor α in human HepG2 liver and U2 osteogenic cancer cell lines

Molecular and Cellular Endocrinology

Volumn 162, Issue 1-2, 2000, Pages 211-220

  Yoon, Kyungsil ^a   Pellaroni, Lea ^a   Ramamoorthy, Kavita ^a   Gaido, Kevin ^b   Safe, Stephen ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b CIIT CENTERS FOR HEALTH RESEARCH   (United States)

Author keywords

Estrogen receptor ; Human HepG2 liver cell lines; U2 osteogenic cancer cell lines

Indexed keywords

2',3',4',5' TETRACHLORO 4 BIPHENYLOL; 2',4',6' TRICHLORO 4 BIPHENYLOL; 2,2' BIS(4 HYDROXYPHENYL) 1,1,1 TRICHLOROETHANE; 4 OCTYLPHENOL; 4,4' ISOPROPYLIDENEDIPHENOL; CHLORDECONE; COMPLEMENT COMPONENT C3; ESTROGEN RECEPTOR ALPHA; FLAVANONE; HYDROXYBIPHENYL; LUCIFERASE; NARINGENIN; NONYLPHENOL; PESTICIDE; PHYTOESTROGEN; RESVERATROL; STILBENE DERIVATIVE; TRICHLOROETHANE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIGAND BINDING; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR BINDING; REPORTER GENE; STRUCTURE ACTIVITY RELATION;

EID: 0034712905     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(99)00261-0     Document Type: Article

References (43)

1. Beato M., Herrlich P., Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell. 83:1995;851-857.
2. Bolger R., Wiese T.E., Ervine K., Nestich S., Checovich W. Rapid screening of environmental chemicals for estrogen receptor binding capacity. Environ. Health Persp. 106:1998;551-557.
3. Bryant H.U., Dere W.H. Selective estrogen receptor modulators; an alternative to hormone replacement therapy. Proc. Soc. Exp. Biol. Med. 217:1998;45-52.
4. Chow J., Tobias J.H., Colston K.W. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J. Clin. Invest. 89:1992;74-78.
5. Clark J.H. Female reproduction and toxicology of estrogens. Korach K.S. Reproductive and Developmental Toxicology. 1998;259-275 Marcel Dekker, New York.
6. Colborn T., Vom Saal F.S., Soto A.M. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ. Health Perspect. 101:1993;378-384.
7. Davis D.L., Bradlow H.L., Wolff M., Woodruff T., Hoel D.G., Anton-Culver H. Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Environ. Health Perspect. 101:1993;372-377.
8. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
9. Farhat M.Y., Lavigne M.C., Ramwell P.W. The vascular protective effects of estrogen. FASEB J. 10:1996;615-624.
10. Gaido K.W., Leonard L.S., Lovell S., Gould J.C., Babaï D., Portier C.J. et al. Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. Toxicol. Appl. Pharmacol. 143:1997;205-212.
11. Gaido, K.W., Leonard, L.S., Maness, S.C., Galluzzo, J.M., McDonnell, D.P., Saville, B. and Safe, S. 1999 Differential interaction of the methoxychlor metabolite HPTE with estrogen receptors alpha and beta. Endocrinology (in press).
12. Gehm B.D., McAndrews J.M., Chien P.-Y., Jameson J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA. 94:1997;14138-14143.
13. Glass C.K., Rose D.W., Rosenfeld M.G. Nuclear receptor coactivators. Curr. Opin. Cell Biol. 9:1997;222-232.
14. Gould C., Leonard L.S., Maness S.C., Wagner B.L., Connor K., Zacharewski T. et al. Bisphenol A interacts with the estrogen receptor α in a distinct manner from estradiol. Mol. Cell. Endocrinol. 142:1998;203-214.
15. Halachmi S., Marden E., Martin G., MacKay H., Abbondanza C., Brown M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science. 264:1994;1455-1458.
16. Hendersen B.E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 48:1988;246-253.
17. Hulka B.S., Liu E.T., Lininger R.A. Steroid hormones and risk of breast cancer. Cancer. 74:1994;1111-1124.
18. Hunter D.S., Hodges L.C., Vonier P.M., Fuchs-Young R., Gottardis M.M., Walker C.L. Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium. Cancer Res. 59:1999;3090-3099.
19. Hutzinger O., Safe S., Zitko V. Preparation, gas chromatography behavior, and spectroscopic properties of hydroxylated chlorobiphenyls. J. Assoc. Offic. Anal. Chem. 57:1974;1061-1067.
20. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., Van der Saag P.T. et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β Endocrinology. 139:1998;4252-4263.
21. Lu R.Q., Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell. Physiol. 179:1999;297-304.
22. MacGregor J.I., Jordan V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50:1998;151-196.
23. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K. et al. The nuclear receptor superfamily: the second decade. Cell. 83:1995;835-839.
24. Mannervik M., Nibu Y., Zhange H.L., Levine M. Transcription-transcriptional coregulators in development. Science. 284:1999;606-609.
25. McDonnell D.P., Clemm D.L., Hermann T., Goldman M.E., Pike J.W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9:1995;659-669.
26. McDonnell D.P., Lieberman B.A., Norris J.A. Development of tissue-selective estrogen receptor modulators. Baird D.T., Schutz G., Krattenmacher R. Organ-Selective Actions of Steroid Hormones. 1995;1-28 Springer-Verlag, Berlin.
27. McGuire W.L., Carbone P.P., Seard M.E., Esche G.C. Estrogen receptors in human breast cancer: an overview. McGuire W.L., Carbone P.P., Volliner E.P. Estrogen Receptors in Human Breast Cancer. 1975;1-7 Raven Press, New York.
28. Mgbonyebi O.P., Russo J., Russo I.H. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int. J. Oncol. 12:1998;865-869.
29. Nishikawa J., Saito K., Goto J., Dakeyama F., Matsuo M., Nishihara T. New screening methods for chemicals with hormonal activities using interaction of nuclear hormone receptor with coactivator. Toxicol. Appl. Pharmacol. 154:1999;76-83.
30. Norris J.D., Paige L.A., Christensen D.J., Chang C.-Y., Huacani M.R., Fan D. et al. Peptide antagonists of the human estrogen receptor. Science. 285:1999;744-746.
31. Onate S.A., Tsai S.Y., Tsai M.J., O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 270:1995;1354-1357.
32. Paige L.A., Christensen D.J., Gron H., Norris J.D., Gottlin E.B., Padilla K.M. et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ERα and ERβ Proc. Natl. Acad. Sci. USA. 96:1999;3999-4004.
33. Ramamoorthy K., Wang F., Chen I.-C., Norris J.D., McDonnell D.P., Gaido K.W. et al. Estrogenic activity of a dieldrin/toxaphene mixture in the mouse uterus, MCF-7 human breast cancer cells and yeast-based estrogen receptor assays: no apparent synergism. Endocrinology. 138:1997;1520-1527.
34. Ruh M.F., Zacharewski T., Connor K., Howell J., Chen I., Safe S. Naringenin: a weakly estrogenic bioflavonoid which exhibits antiestrogenic activity. Biochem. Pharmacol. 50:1995;1485-1493.
35. Safe S. Environmental and dietary estrogens and human health-is there a problem? Environ. Health Perspect. 103:1995;346-351.
36. Safe S. Interactions between hormone and chemicals in breast cancer. Annu. Rev. Pharmacol. Toxicol. 38:1998;121-158.
37. Sharpe R.M., Skakkebaek N.F. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract. Lancet. 341:1993;1392-1395.
38. Sohornni P., Sumpter J.P. Several environmental oestrogens are also anti-androgens. J. Endocrinol. 158:1998;327-339.
39. Tsai M.J., O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily. Ann. Rev. Biochem. 63:1994;451-486.
40. Turner R.T., Evans G.L., Zhang M., Maran A., Sibonga J.C. Is resveratrol an estrogen agonist in growing rats? Endocrinology. 140:1999;50-54.
41. Turner R.T., Riggs B.L., Spelsberg T.C. Skeletal effects of estrogen. Endocr. Rev. 15:1994;275-300.
42. Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.G. et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8:1994;21-30.
43. Voegel J.J., Heine M.J., Tini M., Vivat V., Chambon P., Gronemeyer H. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J. 17:1998;507-519.